SETD2基因改变损害DNA损伤识别并导致白血病化疗耐药
在等基因白血病细胞系和条件性敲除Setd2的小鼠白血病模型中,SETD2突变导致对阿糖胞苷、6-硫鸟嘌呤、多柔比星和依托泊苷等DNA损伤剂耐药,但不影响对L-天冬酰胺酶的敏感性;H3K36me3定位DNA损伤反应组分,SETD2突变损害DDR并减弱凋亡;JIB-04可恢复H3K36me3水平和阿糖胞苷敏感性。
要点
- SETD2突变导致白血病细胞对多种DNA损伤化疗药耐药,但不影响L-天冬酰胺酶敏感性。
- H3K36me3参与招募DNA损伤反应组分,SETD2突变损害DDR并减弱化疗诱导的凋亡。
- KDM4A抑制剂JIB-04可恢复H3K36me3水平及阿糖胞苷敏感性。
核心结论
- SETD2改变是DNA损伤化疗耐药的机制之一,与局部DNA损伤反应缺失一致,并提示针对SETD2突变白血病的潜在治疗策略。
研究设计与样本
- 研究在等基因白血病细胞系和来自Setd2条件性敲除的小鼠白血病中调查SETD2突变对化疗敏感性的影响。
主要发现
- SETD2突变导致对DNA损伤剂阿糖胞苷、6-硫鸟嘌呤、多柔比星和依托泊苷耐药,但不导致对非DNA损伤剂L-天冬酰胺酶耐药。
- H3K36me3定位DNA损伤反应(DDR)通路组分,SETD2突变损害DDR,减弱细胞毒性化疗诱导的凋亡。
- H3K36me3较高的基因组区域突变率较低,SETD2突变后该突变率增加。
- 小鼠模型中Setd2杂合条件性失活缩短MLL-AF9诱导白血病的潜伏期并导致体内对阿糖胞苷治疗耐药,而纯合缺失延迟白血病形成。
- JIB-04(H3K9/36me3去甲基化酶KDM4A抑制剂)治疗恢复H3K36me3水平和对阿糖胞苷的敏感性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in SETD2, encoding the histone 3 lysine 36 trimethyltransferase, are enriched in relapsed acute lymphoblastic leukemia and MLL-rearranged acute leukemia. We investigated the impact of SETD2 mutations on chemotherapy sensitivity in isogenic leukemia cell lines and in murine leukemia generated from a conditional knockout of Setd2. SETD2 mutations led to resistance to DNA-damaging agents, cytarabine, 6-thioguanine, doxorubicin, and etoposide, but not to a non-DNA damaging agent, l-asparaginase. H3K36me3 localizes components of the DNA damage response (DDR) pathway and SETD2 mutation impaired DDR, blunting apoptosis induced by cytotoxic chemotherapy. Consistent with local recruitment of DDR, genomic regions with higher H3K36me3 had a lower mutation rate, which was increased with SETD2 mutation. Heterozygous conditional inactivation of Setd2 in a murine model decreased the latency of MLL-AF9-induced leukemia and caused resistance to cytarabine treatment in vivo, whereas homozygous loss delayed leukemia formation. Treatment with JIB-04, an inhibitor of the H3K9/36me3 demethylase KDM4A, restored H3K36me3 levels and sensitivity to cytarabine. These findings establish SETD2 alteration as a mechanism of resistance to DNA-damaging chemotherapy, consistent with a local loss of DDR, and identify a potential therapeutic strategy to target SETD2-mutant leukemias.
引用
- Mar BG, Chu SH, Kahn JD, et al. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. 2017. PMID: 29018079. doi:10.1182/blood-2017-03-775569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。